BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16640533)

  • 1. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension.
    Perez-Villa F; Cuppoletti A; Rossel V; Vallejos I; Roig E
    Clin Transplant; 2006; 20(2):239-44. PubMed ID: 16640533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation.
    Perez-Villa F; Farrero M; Cardona M; Castel MA; Tatjer I; Penela D; Vallejos I
    Clin Transplant; 2013; 27(1):25-31. PubMed ID: 22861120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
    Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study.
    Martin J; Siegenthaler MP; Friesewinkel O; Fader T; van de Loo A; Trummer G; Berchtold-Herz M; Beyersdorf F
    Eur J Cardiothorac Surg; 2004 Jun; 25(6):971-7. PubMed ID: 15144997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K; Yoshimura N; Taguchi M; Watanabe K; Nakamura T; Ichida F; Miyawaki T
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):346-51. PubMed ID: 20434177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients.
    Torres Macho J; Delgado Jimenez JF; Sanz Salvo J; Gonzalez Mansilla A; Sanchez Sanchez V; Gamez Diez S; Escribano Subias P; Saenz de la Calzada C
    Transplant Proc; 2009; 41(6):2477-9. PubMed ID: 19715956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study.
    von Scheidt W; Costard-Jaeckle A; Stempfle HU; Deng MC; Schwaab B; Haaff B; Naegele H; Mohacsi P; Trautnitz M;
    J Heart Lung Transplant; 2006 Sep; 25(9):1070-6. PubMed ID: 16962468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation.
    Pons J; Leblanc MH; Bernier M; Cantin B; Bourgault C; Bergeron S; Proulx G; Morin J; Nalli C; O'Connor K; Chateauvert N; Sénéchal M
    J Heart Lung Transplant; 2012 Dec; 31(12):1281-7. PubMed ID: 23127754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
    Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
    Givertz MM; Hare JM; Loh E; Gauthier DF; Colucci WS
    J Am Coll Cardiol; 1996 Dec; 28(7):1775-80. PubMed ID: 8962566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report.
    Mogollón MV; Lage E; Cabezón S; Hinojosa R; Ballesteros S; Aranda A; Sobrino JM; Ordóñez A
    Transplant Proc; 2006 Oct; 38(8):2522-3. PubMed ID: 17097987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance?
    Liden H; Haraldsson A; Ricksten SE; Kjellman U; Wiklund L
    Eur J Cardiothorac Surg; 2009 Jun; 35(6):1029-34; discussion 1034-5. PubMed ID: 19211259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
    LaRue SJ; Garcia-Cortes R; Nassif ME; Vader JM; Ray S; Ravichandran A; Rasalingham R; Silvestry SC; Ewald GA; Wang IW; Schilling JD
    Cardiovasc Ther; 2015 Apr; 33(2):50-5. PubMed ID: 25759010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant.
    Klotz S; Wenzelburger F; Stypmann J; Welp H; Drees G; Schmid C; Scheld HH
    Ann Thorac Surg; 2006 Nov; 82(5):1770-3. PubMed ID: 17062245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
    Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E
    J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156
    [No Abstract]   [Full Text] [Related]  

  • 17. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
    Dandel M; Lehmkuhl HB; Mulahasanovic S; Weng Y; Kemper D; Grauhan O; Knosalla C; Hetzer R
    J Heart Lung Transplant; 2007 Sep; 26(9):898-906. PubMed ID: 17845928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of pulmonary hypertension reversibility test with sodium nitroprusside in stratification of early death risk after orthotopic heart transplantation.
    Zakliczynski M; Zebik T; Maruszewski M; Swierad M; Zembala M
    Transplant Proc; 2005 Mar; 37(2):1346-8. PubMed ID: 15848716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients.
    Mikus E; Stepanenko A; Krabatsch T; Loforte A; Dandel M; Lehmkuhl HB; Hetzer R; Potapov EV
    Eur J Cardiothorac Surg; 2011 Oct; 40(4):971-7. PubMed ID: 21354812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.